Dyne Therapeutics (NASDAQ:DYN) Lowered to Sell at StockNews.com

Dyne Therapeutics (NASDAQ:DYN) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

DYN has been the topic of a number of other reports. Chardan Capital increased their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st. Stifel Nicolaus increased their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Oppenheimer reissued an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, Guggenheim increased their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Stock Up 0.6 %

Shares of DYN opened at $34.60 on Monday. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $47.45. The business’s fifty day moving average is $41.43 and its 200 day moving average is $33.43. The stock has a market cap of $3.02 billion, a P/E ratio of -8.72 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, analysts expect that Dyne Therapeutics will post -2.96 EPS for the current year.

Insider Activity

In related news, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the sale, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the sale, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO John Cox acquired 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The disclosure for this purchase can be found here. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. bought a new position in Dyne Therapeutics in the 1st quarter worth about $140,666,000. Vanguard Group Inc. boosted its stake in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after acquiring an additional 2,663,910 shares during the last quarter. Artal Group S.A. boosted its position in shares of Dyne Therapeutics by 24.6% during the 1st quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock valued at $43,095,000 after acquiring an additional 300,000 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock valued at $42,881,000 after acquiring an additional 114,888 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.